Kenneth R. Bridges
Chief Tech/Sci/R&D Officer bij GLOBAL BLOOD THERAPEUTICS, INC.
Profiel
Kenneth R.
Bridges currently works at American Kidney Fund, Inc., as Director from 2022 and Global Blood Therapeutics, Inc., as Medical Director & Vice President-Medical Affairs.
Actieve functies van Kenneth R. Bridges
Bedrijven | Functie | Begin |
---|---|---|
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
American Kidney Fund, Inc.
American Kidney Fund, Inc. Medical/Nursing ServicesHealth Services The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD. | Director/Board Member | 08-03-2022 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
American Kidney Fund, Inc.
American Kidney Fund, Inc. Medical/Nursing ServicesHealth Services The American Kidney Fund provides treatment and financial assistance to patients with chronic kidney disease. It also provides assistance with expenses that insurance will not cover, such as transportation to dialysis, medications, special diet, kidney donor expenses, and other treatments. It also conducts specialty programs that help patients afford treatment during emergency travel and recover from natural disasters. The company was founded in 1971, and is headquartered in Rockville, MD. | Health Services |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |